Biopharma therapeutics and platforms venture funding built momentum in Q2 2026, with 120 rounds raising $9.2B against 115 rounds and $7.1B in Q1; capital climbed nearly 30%, and the average round grew to $86M from $64M, while H1 2026 closed at 235 rounds and $16.3B.
By series, series B led at $3.9B, more than double Q1’s $1.8B, with series A at $2.1B, series C doubling to $1.0B, unspecified private financings at $1.5B, seed easing to $300M, and series D and later falling to $500M from $1.1B.
By therapy area, cancer led with $1.4B across 20 rounds, ahead of neurology at $767M across 13 rounds and ophthalmology at $565M across five rounds, while gastrointestinal posted the largest average round at $250M from a single financing, and autoimmune, pulmonary, cardiovascular, and inflammation drew $360M, $279M, $247M, and $245M respectively, bringing the top areas to 72 rounds and roughly $4.4B.
By modality, biologics dominated at nearly $3.0B across 44 rounds at an average of $73M, well ahead of small molecules at $945M across 21 rounds, gene therapy and vectors at $423M across six rounds, cell therapy at $337M across 11 rounds, immunotherapy at $119M across two rounds, and gene editing and CRISPR at just $9M.
The quarter’s largest rounds spread across neurology, ophthalmology, gastrointestinal, and oncology platforms. Korsana’s roughly $380M round topped the field, backing KRSA-028, a brain-delivered amyloid beta antibody for Alzheimer’s, with a syndicate led by Fairmount and Venrock. Ollin Biosciences raised an oversubscribed $330M series B, co-led by TCGX and ARCH, for its retina franchise led by OLN324 in DME and wet AMD. Anagram Therapeutics secured a $250M commitment from Blackstone Life Sciences for ANG003, an oral enzyme replacement therapy in exocrine pancreatic insufficiency, and CellCentric’s $220M series D, Europe’s largest private biotech financing of 2026 so far, funded the multiple myeloma agent inobrodib. cAMPfield launched with a $180M series A from Frazier Life Sciences around prifemilast, an oral PDE4B inhibitor for IBD. The signal is consistent for mid-stage assets and differentiated platforms, a constructive setup for H2 2026.
Biopharma therapeutics and platforms venture funding gained momentum in Q2 2026, with 120 rounds raising $9.2B, compared with 115 rounds and $7.1B in Q1 2026. Although deal volume rose modestly, total capital raised increased by nearly 30%, while the average financing grew from $64M to $86M per round. This indicates stronger conviction and larger commitments to individual biopharma financings during the quarter. Across the first half of 2026, the sector recorded 235 venture funding rounds and $16.3B in total capital raised.
Biopharma Therapeutics and Platforms Venture Funding Activity by Series
In Q2 2026, biopharma therapeutics and platforms venture funding reached $9.2B across 120 rounds. Series B financings led activity, raising $3.9B, more than double the $1.8B raised in Q1. Series A funding remained strong at $2.1, while series C funding doubled to $1.0B and unspecified private financings increased to $1.5B. Seed funding declined modestly to $300M, and series D and later-stage funding fell to $500M from $1.1B in Q1. Overall, the first half of 2026 generated $16.3B across 235 rounds, with series B and series A accounting for the largest share of venture capital.
Biopharma Therapeutics and Platforms Venture Funding Activity by Top Therapy Areas in Q2 2026
Cancer remained the leading therapy area for biopharma therapeutics and platforms venture funding in Q2 2026, raising $1.4B across 20 rounds. Neurologic followed with $767M across 13 rounds. Ophthalmic attracted $565M through five rounds, producing an average round size of $141M, while gastrointestinal recorded the largest average financing at $250M from a single round. Autoimmune, pulmonary, and cardiovascular companies raised $360M, $279M, and $247M, respectively, while inflammation attracted $245M across only two rounds. Collectively, the listed top therapy areas accounted for 72 funding rounds and approximately $4.4B in Q2 2026.
Â
Biopharma Therapeutics and Platforms Venture Funding Activity by Top Modalities in Q2 2026
In Q2 2026, biologics, including antibody, DNA, RNA, and protein-based technologies, dominated biopharma therapeutics and platforms venture funding, raising nearly $3.0B across 44 rounds at an average round size of $73M. Small molecules ranked second, with $945M raised across 21 rounds, followed by gene therapy and vectors at $423M across six rounds. Cell therapy attracted $337M across 11 rounds, while immunotherapy raised $119M through two financings. Gene editing and CRISPR saw comparatively limited activity, with only $9M raised across two rounds. Overall, Q2 2026 funding reflected a strong preference for biologics and established therapeutic modalities.
Prominent Biopharma Therapeutics and Platforms Venture Funding in Q2 2026
Korsana – Private – $380M – April 2026
Korsana raised approximately $380 million, led by Fairmount and Venrock Healthcare Capital Partners, to advance KRSA-028, a brain-delivered amyloid beta antibody for Alzheimer’s disease built on its Therapeutic Targeting (THETA) platform, using transferrin receptor (TfR1) and Fc engineering. The round follows $175 million in prior seed and series A funding, including a $25 million seed in 2024 and a $150 million series A in September 2025. An April 1, 2026, all-stock merger with Cyclerion will give Korsana a Nasdaq listing, with former Korsana holders expected to own about 98.9% and Cyclerion holders about 1.1%. Funding extends runway into 2029, supports 2027 readouts, and enables Phase 1 testing by mid-2027.
Ollin Biosciences – Series B – $330M – June 2026
Ollin’s oversubscribed $330 million series B, co-led by TCGX and ARCH Venture Partners, funds global Phase 3 development of OLN324 for diabetic macular edema (DME) and wet age-related macular degeneration (wAMD), plus clinical entry for OLN102 in thyroid eye disease and Graves’ disease. In the 164-patient JADE Phase 2 study, OLN324 outperformed faricimab (Vabysmo) on retinal anatomy and showed numerically greater vision gains. Following FDA and EMA engagement, Phase 3 trials are planned for the second half of 2026, including China and South Korea. OLN324, also known as IBI324, is partnered with Innovent Biologics; OLN102 originated from VelaVigo.
Anagram Therapeutics – Series Unspecified – $250M – May 2026
Anagram secured a $250 million commitment from sole investor Blackstone Life Sciences on May 7, 2026, to fund the development, approval, and launch of ANG003, an oral recombinant enzyme replacement therapy for exocrine pancreatic insufficiency (EPI). ANG003 contains lipase, protease, and amylase and is designed to remain active in the gastrointestinal tract. Blackstone Life Sciences, which manages approximately $17 billion, is backing an international Phase 2 study following positive earlier data in EPI associated with cystic fibrosis. The commitment follows more than $30 million from the Cystic Fibrosis Foundation, which funded most development work to date. The investment case centers on lower treatment burden and supply security. ANG003 could become the first non-porcine product in a U.S. market worth roughly $2 billion annually.
CellCentric – Series D – $220M – May 2026
CellCentric closed an oversubscribed $220 million series D on May 6, 2026, led by Venrock Healthcare Capital Partners, marking Europe’s largest private biotech financing in 2026 so far. The capital advances inobrodib (CCS1477), an oral p300/CBP inhibitor for relapsed or refractory multiple myeloma, evaluated in over 500 patients and supported by FDA Fast Track and orphan drug designations. At ASH in December 2025, the 20 mg InoPd cohort delivered a 69% objective response rate across 44 evaluable patients, with 60% at 20 mg and 75% at 30 mg in patients with a median of five prior lines who had failed BCMA and/or T-cell-engager therapy, at least double the 25% to 30% real-world benchmark. Proceeds fund the Phase 2 DOMMINO-1 study in the UK and US, with a primary readout set for 2029, the global Phase 3 DOMMINO-2 trial beginning in the second half of 2026, and combinations with teclistamab and elranatamab.
cAMPfield – Series A – $180M – May 2026
cAMPfield launched with a $180 million series A, led by Frazier Life Sciences, to advance prifemilast (HY1999/HPP737), a once-daily oral PDE4B inhibitor for inflammatory bowel disease (IBD). It holds global rights outside Greater China from Newsoara Biopharma, which acquired the asset from vTv Therapeutics in a deal valued at up to $135 million. cAMPfield is starting a Phase 2b trial in ulcerative colitis and a Phase 2 trial in Crohn’s disease. More than 700 individuals have received prifemilast, including over 250 with a year of exposure, and the drug showed placebo-comparable discontinuation rates and strong Phase 3 plaque psoriasis efficacy.
Also check out Biopharma Therapeutics and Platforms M&A – Q2 2026 Review
